BRAF Biomarkers
News and reporting on BRAF biomarkers.
Foundation Medicine Blood Test Gets FDA Approval as CDx for Pfizer's Braftovi in Colorectal Cancer
The FDA has approved the FoundationOne Liquid CDx assay to identify patients with BRAF V600E alterations eligible for treatment with Braftovi.
AACR Studies Flag Molecular Differences in Colorectal Cancer Patients of African, European Ancestry
Premium
Data presented at the meeting underscored the importance of studying diverse populations in order to improve equity in precision oncology.
NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling
The guidelines recognize the importance of molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for children with high-grade gliomas.
Kinnate Biopharma, Guardant Health Partner for Study of BRAF Mutations in Solid Tumors
Preliminary findings indicate that about half of the 6,000 patients with BRAF alteration-positive cancers harbored Class II and III alterations.
MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial
Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.